Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Xifeng Lu

Ping Dong

Zhilin Chen

Xinlu Li

Xiongxiong He

Shang Wang

Yi Xu

Jiahui Cai

Zhenxue Deng

Min Li

Shanshan Sui

Lihui Dong

Xiandong Zhao

Jiao Xu

Haishan Zang

Jianghui Jing

Bo Jiang

Peng Sun

A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties.

Solid pharmaceutical composition comprising TLR7 agonist

The present application provides a pharmaceutical composition comprising 6-(2-chloro-4-iodophenylamino)-N-(2-hydroxyethoxy)-5-methyl-4-oxo-4,5-dihydrofuro[3,2-c]pyridine-7-carboxamide or a pharmaceutically acceptable salt, a binder, a surface stabilizer and a dispersant, wherein the pharmaceutical composition can be dispersed in water to form a pharmaceutical suspension having a median particle size, X50, of 0.5 &#x3bc;m to 4.0 &#x3bc;m. Also disclosed are a preparation method thereof and the use thereof for treating cancers.

Pharmaceutical composition of MEK inhibitor and preparation method thereof

Growing community of inventors

Lianyungang, China

Xifeng Lu